EP2282982A1 - Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production - Google Patents

Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production

Info

Publication number
EP2282982A1
EP2282982A1 EP09749581A EP09749581A EP2282982A1 EP 2282982 A1 EP2282982 A1 EP 2282982A1 EP 09749581 A EP09749581 A EP 09749581A EP 09749581 A EP09749581 A EP 09749581A EP 2282982 A1 EP2282982 A1 EP 2282982A1
Authority
EP
European Patent Office
Prior art keywords
unbranched
branched
alkyl
compounds
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09749581A
Other languages
German (de)
English (en)
Inventor
Ludger Dinkelborg
Mathias Berndt
Matthias Friebe
Heribert Schmitt-Willich
Detlev Sülzle
Norman Koglin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Molecular Imaging SA
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39970942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2282982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Priority to EP09749581A priority Critical patent/EP2282982A1/fr
Publication of EP2282982A1 publication Critical patent/EP2282982A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles

Definitions

  • the invention relates to the articles characterized in the claims, namely [F-18] labeled L-glutamic acid derivatives and [F-18] labeled L-glutamine derivatives of the general formula I, as well as their use and processes for their preparation.
  • PET technology positron emission tomography
  • the sensitivity and specificity of PET technology depends largely on the signaling agent used (tracer) and its distribution in the body.
  • signaling agent used tracer
  • suitable tracers one seeks to exploit certain properties of tumors that distinguish tumor tissue from healthy, surrounding tissue.
  • the preferred commercially used isotope used for PET is 18 F. 18 F has a short half-life of less than 2 hours, which places particular demands on the preparation of suitable tracers.
  • FDG [ 18 F] 2-fluorodeoxyglucose
  • Tumor cells usually have an increased glucose metabolism compared to surrounding cells of normal tissue.
  • FDG fluorodeoxyglucose
  • 18 F amino acids for the measurement of the speed rate of protein synthesis, most of the other derivatives for the measurement of direct cell uptake in the tumor Known 18 F.. labeled amino acids are derived, for example, from tyrosine, phenylalanine, proline, asparagine and unnatural amino acids (for example, J Nucl Med 1991, 32: 1338-1346, J Nucl Med 1996, 37: 320-325 , J Nucl Med 2001; 42: 752-754 and J Nucl Med 1999; 40: 331-338).
  • Glutamic acid and glutamine are not known as 18 F-labeled derivatives, whereas non-radioactive fluorinated glutamic and glutamic acid derivatives are known; so z.
  • those attached to the ⁇ position e.g., (review): Amino Acids. (2003) Apr; 24 (3): 245-61) or to the ⁇ position (e.g., Tetrahedron Lett ; 14; 1989; 1799-1802, J. Org. Chem. 54; 2; 1989; 498-500, Tetrahedron: Asymmetry; 12; 9; 2001; 1303-1312).
  • Glutamic acid derivatives which have protective groups on the chemical functionalities and a leaving group in the ⁇ or ⁇ position have already been reported in the past.
  • glutamate has been reported as the mesylate or bromide in the ⁇ position, whose acid and amine functions have been provided with ester and Z-protecting groups, respectively (J. Chem. Soc., Perkin Trans., 1986, 1323-1328) or, for example of ⁇ -chloro-glutamic acid without protecting groups (Synthesis; (1973); 44-46).
  • the object of the present invention is to find novel compounds which are suitable for PET-based diagnosis in [ 18 F] labeled form.
  • A is a) hydroxyl, b) branched or unbranched C 1 -C 5 -alkoxy, c) branched or unbranched hydroxy C 1 -C 5 -alkoxy, d) branched or unbranched C 1 -C 5 -alkyl (OC 1 -) C 4 SlKyI) n -OC 1 -C 4 alkyl, e) N (C 1 -C 5 alkyl) 2l f) NH 2 ,
  • G for a) hydroxyl, b) OZ, b) branched or unbranched 0-C 1 -C 5 -alkyl, c) branched or unbranched 0-C 2 -C 5 -alkenyl, d) branched or unbranched 0-C 1 -C 5 (alkyl 0-C 1 -C 4) n -O-Ci-C 4 alkyl, e) branched or unbranched 0-C 2 -C 5 alkynyl, or f) triphenylmethoxy is alkyl,
  • R 1 and R 2 for a) hydrogen, b) branched or unbranched 18 FC 1 -C 5 alkoxy, c) branched or unbranched 18 FC 1 -C 5 alkyl, d) branched or unbranched 18 FC 2 -C 5 alkenyl, e ) branched or unbranched 18 F-C 2 -C 5 alkynyl, f) hydroxy, g) branched or unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy wherein alkyl is optionally interrupted by one or more O, S, or N, with the proviso that one of the substituents R 1 or R 2 contains exactly one 18 F isotope and the other substituent does not contain an 18 F isotope, with Given that R 1 is not hydrogen,
  • L is a) branched or unbranched Ci-C 5 alkyl, b) branched or unbranched C 2 -C 5 alkenyl, c) branched or unbranched C 1 -C 5 AIkVl- (OC 1 -C 4 alkyl) n -O-C r C 4 alkyl or d) branched or unbranched C 2 -C 5 alkynyl,
  • Z is a metal cation equivalent
  • n 0, 1, 2 or 3.
  • Preferred compounds of the invention according to the formula (I) are characterized in that A is a) hydroxyl, b) methoxy, c) ethoxy, d) propoxy, e) NMe 2 , f) NEt 2 , g) NH 2 , h ) N (H) -L, i) OL or
  • A is a) hydroxyl, b) methoxy, c) ethoxy, d) NMe 2 , e) NH 2 , or f) N (H) -L.
  • Particularly preferred compounds of the invention according to the formula (I) are characterized in that A is a) hydroxyl, b) branched or unbranched C 1 -C 5 alkoxy or C) NH 2 .
  • Preferred compounds of the invention according to the formula (I) are characterized in that
  • Preferred compounds of the invention according to the formula (I) are characterized in that A is NH 2 .
  • Preferred compounds of the invention according to the formula (I) are characterized in that G for a) hydroxyl, b) branched or unbranched 0-Ci-C 4 alkyl, or c) 0-C 2 H 4 -OMe
  • G is a) hydroxyl, or b) branched or unbranched OC r C 4 alkyl.
  • Particularly preferred compounds of the invention according to the formula (I) are characterized in that G is a) hydroxyl, or b) ethoxy.
  • Particularly preferred compounds of the invention according to the formula (I) are characterized in that G is hydroxyl.
  • R 1 and R 2 is a) hydrogen, b) branched or unbranched 18 F-C 1 -C 5 alkoxy, c) branched or unbranched 18 F-C 1 -C 5 Alkyl, d) branched or unbranched 18 FC 3 -C 5 alkenyl, e) branched or unbranched 18 FC 3 -C 5 alkynyl, f) hydroxyl, g) branched or unbranched Ci-C 5 alkyl or h) branched or unbranched C 1 -C 5 -alkoxy,
  • Preferred compounds of the invention according to the formula (I) are characterized in that
  • R 1 and R 2 for a) hydrogen, b) branched or unbranched 18 FC 2 -C 4 alkoxy, c) branched or unbranched 18 FC 3 -C 5 alkyl, d) branched or unbranched 18 FC 3 -C 5 alkenyl, e ) branched or unbranched 18 F-C 3 -C 5 alkynyl, f) hydroxy, g) branched or unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that one of the substituents R 1 or R 2 contains exactly one 18 F isotope and the other substituent does not contain an 18 F isotope, with the proviso that R 1 is not hydrogen,
  • R 1 is a) branched or unbranched 18 FC 2 alkoxy or b) branched or unbranched 18 FC 3 alkyl.
  • Unbranched 18 FC 2 alkoxy is 18 F-ethoxy.
  • Unbranched 18 FC 3 alkyl is 18 F-propyl.
  • Another particular subject of the invention are compounds of general formula I wherein R 1 is 18 F-ethoxy or 18 F-propyl and R 2 is hydrogen.
  • R 1 is selected from the group consisting of 18 F-ethoxy, 18 F-propoxy, 18 F-ethyl and 18 F-propyl and R 2 is hydrogen.
  • Preferred compounds of the invention according to the formula (I) are characterized in that L represents a) methyl, b) ethyl, c) propyl, d) isopropyl, e) -C 2 H 4 -OMe, or f) - C 2 H 4 -OC 2 H 4 -OMe stands.
  • Particularly preferred compounds of the invention according to the formula (I) are characterized in that L is a) methyl or b) ethyl.
  • Z is selected from the group Na + , K + , Ca 2+ and Mg 2+ .
  • Preferred Z is Na + .
  • the process for the preparation of the compounds of general formula (I) according to the invention is characterized in that one or more protecting groups of a compound of formula (II) is or will be eliminated.
  • the compounds of the formula (I) according to the invention can also be present as zwitterions or salts at physiological pH 7.4, as known to the person skilled in the art.
  • the present invention thus relates to compounds of the general formula (II):
  • a ' is a) hydroxyl, b) branched or unbranched Ci-C 5 alkoxy, c) branched or unbranched hydroxy Ci-C 5 alkoxy, d) branched or unbranched 0-CrC 5 A ⁇ yI- (OC 1 -C 4 alkyl) n -OdC 4 alkyl, e) N (C 1 -C 5 alkylF, f) NH 2 , g) N (H) -L ' , or h) OL ' stands,
  • G ' for a) hydroxyl, b) OZ ' , c) branched or unbranched OC 1 -C 5 alkyl, d) branched or unbranched 0-C 2 -C 5 alkenyl, e) branched or unbranched 0-C 1 -C 5 alkyl (O-C 4 alkyl J n -OC 1 -C 4 alkyl, f) branched or unbranched 0-C 2 -C 5 alkynyl, or g) triphenylmethoxy group,
  • R 1 and R 2 for a) hydrogen, b) branched or unbranched 18 FC 1 -C 5 alkoxy, c) branched or unbranched 18 FC 1 -C 5 alkyl, d) branched or unbranched 18 FC 2 -C 5 alkenyl, e ) branched or unbranched 18 FC 2 -C 5 alkynyl, f) hydroxyl, g) branched or unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy, wherein alkyl is optionally substituted by one or more O , S, or N is interrupted, with the proviso that exactly one of the substituents R 1 or R 2 is exactly one 18 F
  • Q is for a) N (H) -tert-butoxycarbonyl, b) N (H) -allyloxycarbonyl, c) N (H) -benzyloxycarbonyl, d) N (H) -ethoxycarbonyl, e) N (H) -methoxycarbonyl, f ) N (H) -propoxycarbonyl, e) N (H) -2,2,2-trichloroethoxycarbonyl, f) N (H) -1, 1-dimethylpropynyl, g) N (H) -I-methyl-1-phenylethoxycarbonyl, h) N (H) -I-methyl-1- (4-biphenylyl) -ethoxycarbonyl , i) N (H) -cyclobutylcarbonyl, j) N (H) -I-methylcyclobutylcarbonyl, k) N (H) -vinylcarbony
  • L ' is a) branched or unbranched Ci-C 5 alkyl, b) branched or unbranched C 2 -C 5 alkenyl, c) branched or unbranched Ci-C5 Alkyi- (O-Ci-C4alkyl) n -O- Ci-C 4 alkyl, or d) branched or unbranched C 2 -C 5 alkynyl,
  • X 'and X "independently of one another represent a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, c) substituted or unsubstituted aralkyl or d) substituted or unsubstituted heteroaryl, Z 'is a metal cation equivalent, and
  • n 0, 1, 2 or 3.
  • Preferred compounds of the invention according to the formula (II) are characterized in that A 'is a) hydroxyl, b) methoxy, c) ethoxy, d) propoxy, e) NMe 2 , O NEt 2 , g) NH 2 , h ) N (H) -L or i) OL, J) OZ.
  • Particularly preferred compounds of the invention according to the formula (II) are characterized in that A ' for a) hydroxyl, b) branched or unbranched C 1 -C 5 alkoxy or C) NH 2 is.
  • Preferred compounds of the invention according to the formula (II) are characterized in that A 'is tert-butoxy.
  • Preferred compounds of the invention according to the formula (II) are characterized in that
  • Preferred compounds of the invention according to the formula (II) are characterized in that A 'is ethoxy.
  • Preferred compounds of the invention according to the formula (II) are characterized in that G 'is a) hydroxyl, b) branched or unbranched 0-C 1 -C 4 -alkyl, or c) 0-C 2 H 4 -OMe
  • Particularly preferred compounds of the invention according to the formula (II) are characterized in that G 'is a) hydroxyl, b) methoxy, c) ethoxy or d) tert-butoxy.
  • Preferred compounds of the invention according to the formula (II) are characterized in that
  • R 1 and R 2 for a) hydrogen, b) branched or unbranched 18 FC 1 -C 5 alkoxy, c) branched or unbranched 18 FC 1 -C 5 alkyl, d) branched or unbranched 18 FC 3 -C 5 alkenyl, e ) branched or unbranched 18 F-C 3 -C 5 alkynyl, f) hydroxy, g branched or) unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that exactly one of Substituents R 1 or R 2 exactly one 18 F isotope and the other substituent does not contain an 18 F isotope, with the
  • Preferred compounds of the invention according to formula (II) are characterized in that R 1 and R 2 is a) hydrogen, b) branched or unbranched 18 F-C 2 -C 4 alkoxy, c) branched or unbranched 18 F-C 3 -C 5 alkyl, d) branched or unbranched 18 F-C 3 -C 5 alkenyl, or e) branched or unbranched 18 F-C 3 -C 5 alkynyl, f) hydroxy, g) branched or unbranched C 1 -C 5 alkyl or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that exactly one of the substituents R 1 or R 2 contains exactly one 18 F isotope and the other substituent is hydrogen, with the Given that R 1 is not hydrogen.
  • Preferred compounds of the invention according to the formula (II) are characterized in that
  • R 1 is selected from the group 18 F-ethoxy, 18 F-propoxy, 18 F-ethyl and 18 F-propyl and R 2 is hydrogen.
  • R 1 is a) branched or unbranched 18 FC 2 alkoxy or b) branched or unbranched 18 FC 3 alkyl.
  • Unbranched 18 FC 2 alkoxy is 18 F-ethoxy.
  • Unbranched 18 FC 3 alkyl is 18 F-propyl.
  • Another particular subject of the invention are compounds of general formula (I) wherein R 1 is 18 F-ethoxy or 18 F-propyl and R 2 is hydrogen.
  • Preferred compounds of the invention according to the formula (II) are characterized in that L 'is a) methyl, b) ethyl, c) propyl, d) iso-propyl, e) -C 2 H 4 -OMe, f) -C 2 H 4 -OC 2 H 4 -OCH 3 or g) tert-butyl.
  • Particularly preferred compounds of the invention according to the formula (II) are characterized in that L 'is a) methyl, b) ethyl or c) tert-butyl.
  • Z ' is selected from the group Na + , K + , Ca 2+ and Mg 2+ .
  • Preferred Z ' is Na + .
  • Preferred compounds of the invention according to the formula (II) are characterized in that Q is a) N (H) -tert-butoxycarbonyl, b) N (H) -benzyloxycarbonyl, c) N- (tert-butoxycarbonyl) 2 , or d) stands.
  • Particularly preferred compounds of the invention according to formula (II) are characterized in that Q is a) N (H) -tert-butoxycarbonyl, or b) stands.
  • Q is N (H) -tert-butoxycarbonyl.
  • Preferred compounds of the invention according to the formula (II) are characterized in that
  • X * and X "independently of one another represent a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl or c) substituted or unsubstituted aralkyl.
  • X ' and X "independently of one another represent a) branched or unbranched C 1 -C 5 -alkyl, or b) substituted or unsubstituted aryl.
  • X ' and X " is phenyl or substituted in 2-position phenyl.
  • the process for preparing the compounds of the general formula (II) according to the invention is characterized in that the majority of the compound of the formula (II) can be formed from a compound of the formula (III) after introduction of the 18 F isotope.
  • the present invention thus relates to compounds of the general formula (III):
  • R 3 and R 4 for a) hydrogen, b) branched or unbranched EC 1 -C 5 alkoxy, c) branched or unbranched EC 1 -C 5 alkyl, d) branched or unbranched EC 2 -C 5 alkenyl, e) branched or unbranched EC 2 -C 5 alkynyl, f) hydroxyl, g) branched or unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy, where alkyl is optionally substituted by one or more O, S, or N is interrupted, with the proviso that exactly one of the substituents R 3 or R 4 contains an E and the other substituent does not contain E, with the proviso that R 3 is not hydrogen,
  • X ' and X "independently of one another are a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, c) substituted or unsubstituted alkylaryl or d) substituted or unsubstituted heteroaryl,
  • Preferred compounds of the invention according to the general formula (III) are characterized in that A "represents a) branched or unbranched C 1 -C 5 alkoxy, or b) NH 2 .
  • Preferred compounds of the invention according to the general formula (III) are characterized in that A "is methoxy.
  • Preferred compounds of the invention according to the general formula (III) are characterized in that A "for
  • Preferred compounds of the invention according to the general formula (III) are characterized in that A " for
  • Preferred compounds of the invention according to the general formula (III) are characterized in that A "for tert-butoxy is.
  • Preferred compounds of the invention according to general formula (III) are characterized in that G 'is a) branched or unbranched O-C1-C5 alkyl, b) branched or unbranched 0-C 2 -C 5 alkenyl, c) branched or unbranched 0-C 1 -Cs AlRyI- (OC 1 -C 4 alkyl) n -O-CrC 4 alkyl, or e) triphenylmethoxy.
  • Particularly preferred compounds of the invention according to the general formula (III) are characterized in that G "is a) tert-butoxy.
  • R 3 and R 4 are a) hydrogen, b) branched or unbranched EC 1 -C 5 alkoxy, c) branched or unbranched EC 1 -C 5 alkyl , d) branched or unbranched EC 3 -C 5 alkenyl, e) branched or unbranched E-Ca-C 5 alkynyl, f) hydroxyl, g) branched or unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that exactly one of the substituents R 3 or R 4 contains an E and the other substituent no E with the proviso that R 3 is not hydrogen,
  • R 3 and R 4 are a) hydrogen, b) branched or unbranched EC 2 -C 4 alkoxy, c) branched or unbranched EC 3 -C 5 alkyl d) branched or unbranched EC 3 -C 5 alkenyl, e) branched or unbranched C 3 -C 5 -alkynyl, f) branched or unbranched C 1 -C 5 -alkyl or g) branched or unbranched C 1 -C 5 -alkoxy, with the proviso that exactly one of the substituents R 3 or R 4 contains an E and the other substituent is hydrogen, with the proviso that
  • R 3 is not hydrogen.
  • Preferred compounds of the invention according to the general formula (III) are characterized in that R 3 and R 4 are a) hydrogen, b) branched or unbranched EC 2 alkoxy, c) branched or unbranched EC 3 alkyl, d) branched or unbranched EC 3 alkenyl, e) branched or unbranched EC 3 alkynyl, f) hydroxyl, g) branched or unbranched C 1 -C 5 alkyl or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that exactly one the substituent R 3 or R 4 contains an E and the respective other substituent does not contain E,
  • R 3 is a) branched or unbranched EC 2 alkoxy or b) branched or unbranched EC 3 alkyl.
  • Unbranched EC 2 alkoxy is E-ethoxy.
  • Unbranched EC 3 alkyl is E-propyl.
  • Another particular subject of the invention are compounds of the general formula
  • R 3 is E-ethoxy or E-propyl and R 4 is hydrogen.
  • E is a leaving group which is known or obvious to one skilled in the art and which is e.g. in Synthesis (1982), pages 85-125, Table 2, page 86; Carey and Sundberg, Organic Synthesis, (1995), pages 279-281, Table 5.8; or Netscher, Recent Res. Dev. Org. Chem., 2003, 7, 71-83, scheme 1, 2, 10 and 15, or Jerry March, Advanced Organic Chemistry, 4th edition, John Wiley and Sons, p.351 - 56 and 642-653) are described or are not limited thereto.
  • Preferred compounds of the invention according to the formula (III) are characterized in that E for
  • Halogen or sulphonyloxy stands.
  • Preferred halogens are iodo, bromo and chloro.
  • Preferred sulfonyloxy are methanesulfonyloxy, trifluoromethanesulfonyloxy, nonafluorobutyloxy, tosyloxy, and nosyloxy.
  • Preferred compounds of the invention according to the general formula (III) are characterized in that E is a) chloro, b) bromo, c) methanesulfonyloxy, d) trifluoromethanesulfonyloxy, e) nonafluorobutyloxy, f) tosyloxy or g) iodo,
  • Preferred compounds of the invention according to the general formula (III) are characterized in that E is a) chloro, b) bromo, c) methanesulfonyloxy, d) trifluoromethanesulfonyloxy, e) tosyloxy or f) iodo.
  • Particularly preferred compounds of the invention according to the general formula (III) are characterized in that E is a) bromo, or b) methanesulfonyloxy.
  • Preferred compounds of the invention according to the general formula (III) are characterized in that Q 'is (a) N (H) -tert-butoxycarbonyl, b) N (H) -benzyloxycarbonyl, c) N (H) -trityl, or d) stands.
  • Preferred compounds of the invention according to the formula (III) are characterized in that
  • Preferred compounds of the invention according to the formula (III) are characterized in that L "is a) methyl, b) ethyl, c) propyl, d) iso-propyl, e) -C 2 H 4 -OMe, or f) -C 2 H 4 -OC 2 H 4 -OMe. Further preferred compounds of the invention according to the formula (III) are characterized in that L "is a) methyl, or b) ethyl.
  • Preferred compounds of the invention according to the formula (III) are characterized in that
  • X ' and X " independently of one another represent a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, or c) aralkyl.
  • Ci-C 5 alkyl a) branched or unbranched Ci-C 5 alkyl, and b) substituted or unsubstituted aryl.
  • Particularly preferred compounds of the invention according to the formula (III) are characterized in that X 'and X "is phenyl or substituted in 2-position phenyl.
  • Z ' is selected from the group Na + , K + , Ca 2+ and Mg 2+ .
  • Preferred Z ' is Na + .
  • the present invention thus relates to the use of compounds of the formula (IV) for the preparation of compounds of the formula (I) or (II):
  • G '" for a) branched or unbranched OC 1 -C 5 alkyl, b) branched or unbranched 0-C 2 -C 5 alkenyl, c) branched or unbranched 0-C 1 -C 5 AlkYl- (O-CrC 4 BIkYl ) n is -OC 1 -C 4 alkyl, d) branched or unbranched 0-C 2 -C 5 alkynyl, or e) triphenylmethoxy,
  • R 5 and R 6 for a) hydrogen b) hydroxyl, c) branched or unbranched C 1 -C 5 alkyl, d) branched or unbranched C 1 -C 5 alkoxy or e) R 7 -E ' , wherein alkyl optionally by one or more O, S, or N is interrupted, provided that exactly one of the substituents R 5 or R 6 contains one E ' and the other substituent does not contain E ' , with the proviso that R 5 is not hydrogen,
  • R 7 is a) branched or unbranched C 1 -C 5 alkoxy, b) branched or unbranched C 1 -C 5 alkyl, c) branched or unbranched C 2 -C 5 alkenyl, or d) branched or unbranched C 2 -C 5 Alkynyl, Q ' "for a) N-tert-butoxycarbonyl, b) N-allyloxycarbonyl, c) N-benzyloxycarbonyl, d) N-ethoxycarbonyl, e) N-methoxycarbonyl, f) N-propoxycarbonyl, g) N-2,2, 2-trichloroethoxycarbonyl, h) hydrogen, i) N-1-methyl-phenyl-ethoxycarbonyl, j) N-1-methyl-1- (4-biphenylyl) -ethoxycarbonyl, k) N-cyclobutylcarbonyl, I) N-1
  • Particularly preferred compounds of the invention according to the formula (IV) are characterized in that G '" for a) branched or unbranched 0-C 1 -C 5 alkyl, b) branched or unbranched OC 2 -C 5 alkenyl, c) branched or unbranched OC 1 -C 5 AIKyI- (O-Ci-C 4 alkyl) n -OC- ⁇ -C 4 alkyl, or e) triphenylmethoxy.
  • G ' represents a) methoxy, b) ethoxy or c) tert-butoxy.
  • G '" represents a) tert-butoxy
  • E ' is a leaving group which is known or obvious to one skilled in the art and which is e.g. in Synthesis (1982), pages 85-125, Table 2, page 86; Carey and Sundberg,
  • Preferred compounds of the invention according to formula (III) are characterized in that E 'is for Halogen or sulphonyloxy stands.
  • Preferred halogens are iodo, bromo and chloro.
  • Preferred sulfonyloxy are methanesulfonyloxy, trifluoromethanesulfonyloxy, nonafluorobutyloxy, tosyloxy, and nosyloxy.
  • Preferred compounds of the invention according to the general formula (IV) are characterized in that E 'is a) chloro, b) bromo, c) methanesulfonyloxy, d) trifluoromethanesulfonyloxy, e) nonafluorobutyloxy, f) tosyloxy or g) iodo,
  • Preferred compounds of the invention according to formula (IV) are characterized in that E 'is a) chloro, b) bromo, c) methanesulfonyloxy, d) trifluoromethanesulfonyloxy, e) nonafluorobutyloxy, f) tosyloxy or g) iodo,
  • Preferred compounds of the invention according to formula (IV) are characterized in that E ' for a) bromo, b) methanesulfonyloxy, d) trifluoromethanesulfonyloxy or c) trifluoromesyloxy.
  • Preferred compounds of the invention according to the formula (IV) are characterized in that
  • Preferred compounds of the invention according to the formula (IV) are characterized in that X 'and X "independently of one another are a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, or c) aralkyl.
  • X ' and X " independently of one another represent a) branched or unbranched C 1 -C 5 -alkyl or b) substituted or unsubstituted aryl.
  • Particularly preferred compounds of the invention according to the formula (IV) are characterized in that X ' and X "is phenyl or phenyl substituted in the 2-position.
  • R 5 and R 6 are a) hydrogen b) hydroxyl, c) branched or unbranched C 1 -C 5 alkyl, d) branched or unbranched C 1 - C 5 alkoxy or e) R 7 -E ' with the proviso that exactly one of the substituents R 5 or R 6 includes one E ' and the other substituent does not contain E ' , with the proviso that R 5 does not
  • R 5 and R 6 are a) hydrogen, b) hydroxyl, c) branched or unbranched C 3 -C 5 alkyl, d) branched or unbranched C 3 C 5 alkoxy or e) R 7 -E ' , with the proviso that exactly one of the substituents R 5 or R 6 contains an E ' and the other substituent does not contain E ' ,
  • E ' is a) chloro, b) bromo, c) mesyloxy, d) trifluoromethylsulfonyloxy, e) nonafluorobutyloxy, f) tosyloxy or g) iodo,
  • R 7 is a) branched or unbranched C 1 -C 5 alkoxy, b) branched or unbranched C 1 -C 5 alkyl, c) branched or unbranched C 2 -C 5 alkenyl or d) branched or unbranched C 2 -C 5 alkynyl stands,
  • the present invention relates to an imaging kit containing compounds of the general formula IM or IV.
  • the present invention relates to pharmaceutical compositions containing compounds of general formula I, II, III or IV and suitable pharmaceutical carrier substances.
  • Preferred compounds according to formula I or II characterized in that the compounds in a dose range of 150 MBq - 370 MBq are particularly suitable.
  • Compounds according to formula I, or II for use as medicaments Compounds according to formula I, or II for use in tumor imaging. Use of compounds of formula I, II, III or IV for the manufacture of a medicament for tumor imaging.
  • the process for the preparation of the compounds of general formula (I) or (II) according to the invention is characterized in that the majority of the compounds of formula (I) or (II), from a compound of the compounds of general formula (IV) after introduction of the 18 F isotope can arise.
  • the present invention relates to compounds of general formula (IV).
  • the present invention relates to compounds of general formula (I) or (II) and
  • the compounds of the general formula I or II and their preferred embodiments are used as medicaments.
  • the compounds of the general formula I or II according to the invention and their preferred embodiments are used in the diagnosis / imaging of physiological or pathological conditions.
  • These compounds are preferably used in non-invasive PET-based diagnosis on the human or animal body.
  • the compounds of the general formula I or II according to the invention and their preferred embodiments are particularly preferably used in the diagnosis of tumor diseases.
  • tumors are malignancies of the gastrointestinal or colorectal tract, liver, pancreas, kidney, bladder, thyroid, prostate, endometrial, ovarian, testes, melanoma, small cell and non-small cell lung carcinoma, dysplastic oral mucosa carcinoma, invasive oral cancer;
  • Breast cancer including hormone-dependent and hormone-independent breast cancer, squamous cell carcinoma, neurological cancers including neuroblastoma, glioma, astrocytoma, osteosarcoma, meningioma; soft tissue sarcoma;
  • Hemangioam and endocrine tumors including pituitary adenomas, chromocytomas, paragangliomas, haematological malignancies including lymphoma and leukemias; or metastases of any of the above tumors.
  • the compounds of the general formula I or II according to the invention and their preferred embodiments are used for the preparation of a medicament for the diagnosis of tumor diseases.
  • tumors are malignancies of the gastrointestinal or colorectal tract, liver, pancreas, kidney, bladder, thyroid, prostate, endometrial, ovarian, testes, melanoma, small cell and non-small cell bronchial carcinoma, dysplastic oral mucosa Carcinoma, invasive oral cancer;
  • Breast cancer including hormone-dependent and hormone-independent breast cancer, squamous cell carcinoma, neurological cancers including neuroblastoma, glioma, astrocytoma, osteosarcoma, meningioma, soft tissue sarcoma;
  • Hemangioam and endocrine tumors including pituitary adenomas, chromocytomas, paragangliomas, haematological malignancies including lymphoma and leukemias; or metastases of any of the above tumors.
  • the invention relates to pharmaceutical preparations which contain at least one compound of the formula I, II, III or IV and a pharmaceutically acceptable carrier.
  • a pharmaceutical preparation which, in addition to the active ingredient for enteral or parenteral administration, suitable pharmaceutical, organic or inorganic inert carrier materials, such as, water, Gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as, water, Gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • the invention relates to a device (kit) containing at least one compound of formula I, II, III, or IV.
  • A is a) hydroxyl, b) branched or unbranched C 1 -C 5 -alkoxy, c) branched or unbranched hydroxy C 1 -C 5 -alkoxy, d) branched or unbranched 0-C 1 -C 5 -alkyl (OC 1 -C 4 8IkVl) n -OC 1 -C 4 alkyl, e) N (C 1 -C 5 AlKyl) 2 .
  • G for a) hydroxyl, b) OZ, b) branched or unbranched OC 1 -C 5 alkyl, c) branched or unbranched 0-C 2 -C 5 alkenyl, d) branched or unbranched 0-Ci-C 5 alkyl ( O-Ci-C 4 8Kyl) n -OC 1 -C 4 alkyl, e) branched or unbranched 0-C 2 -C 5 alkynyl, or f) triphenylmethoxy,
  • R 1 and R 2 for a) hydrogen, b) branched or unbranched 18 FC 2 -C 5 alkoxy, c) branched or unbranched 18 FC 1 -C 5 alkyl, d) branched or unbranched 18 FC 2 -C 5 alkenyl, e) branched or unbranched 18 FC 2 -C 5 alkynyl, f) hydroxyl, g) branched or unbranched C 1 -C 5 alkyl or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that one of the substituents R 1 or R 2 is exactly one 18 F isotope and the other substituent does not contain an 18 F isotope, with the proviso that R 1 is not hydrogen,
  • L for a) branched or unbranched C 1 -C 5 -alkyl, b) branched or unbranched C 2 -C 5 -alkenyl, c) branched or unbranched C 1 -C 5 -alkyl (OC 1 -C 4 -8-yl) n is -OC 1 -C 4 alkyl or d) branched or unbranched C 2 -C 5 alkynyl,
  • Z is a metal cation equivalent
  • n 0, 1, 2 or 3.
  • R 1 is selected from the group 18 F-methoxy, 18 F-ethoxy, 18 F-propoxy, 18 F-ethyl and 18 F-propyl and R 2 is hydrogen.
  • a compound according to claims 1 to 3 characterized in that R 1 is 18 F and R 2 is hydrogen.
  • a ' is a) hydroxyl, b) branched or unbranched -C 5 alkoxy, c) branched or unbranched hydroxy Ci-C 5 alkoxy, d) branched or unbranched 0-C 1 -C 5 alkyl (OC r C 4 8IkYl ) n -OC 1 -C 4 alkyl, e) N (C 1 -C 5 alkyl) 2> f) NH 2 ,
  • G ' for a) hydroxyl, b) OZ ' , c) branched or unbranched 0-C 1 -C 5 alkyl, d) branched or unbranched 0-C 2 -C 5 acyl, e) branched or unbranched OC 1 -C 5 AIKyI- (OC 1 -C 4 alkyl) n -O-CrC 4 alkyl, f) branched or unbranched 0-C 2 -C 5 alkynyl, or g) triphenylmethoxy,
  • R 1 and R 2 for a) hydrogen, i) branched or unbranched 18 FC 2 -C 5 alkoxy, j) branched or unbranched 18 FC 1 -C 5 alkyl, k) branched or unbranched 18 FC 2 -C 5 acyl, I ) branched or unbranched 18 F-C 2 -C 5 alkynyl, m) hydroxyl, n) branched or unbranched C 1 -C 5 alkyl, or o) branched or unbranched C 1 -C 5 alkoxy, with the proviso that exactly one of Substituent R 1 or R 2 contains exactly one 18 F isotope and the other substituent does not contain an 18 F isotope, with the proviso that R 1 is not hydrogen,
  • L ' is a) branched or unbranched Ci-C 5 alkyl, b) branched or unbranched C 2 -C 5 alkenyl, c) branched or unbranched Ci-C 5 alkyl (ODC 4 alkyl J n -OC 1 -C 4 alkyl or d) branched or unbranched C 2 -C 5 alkynyl,
  • X ' and X " independently of one another represent a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, c) substituted or unsubstituted aralkyl or d) substituted or unsubstituted heteroaryl,
  • n 0, 1, 2 or 3.
  • R 1 is selected from the group 18 F-ethoxy, 18 F-propoxy, 18 F-ethyl and 18 F-propyl and R 2 is hydrogen.
  • a compound according to claim 14 characterized in that G is methoxy.
  • a compound according to claims 10 to 16 characterized in that Q is selected from the group N (H) -tert-butoxycarbonyl, N (H) -benzyloxycarbonyl and
  • X and X ' independently of one another are a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, c) substituted or unsubstituted aralkyl or d) substituted or unsubstituted heteroaryl. 18) A compound according to claim 17, characterized in that Q is N (H) -tert-butoxycarbonyl.
  • R 3 and R 4 for a) hydrogen, b) branched or unbranched EC 2 -C 5 alkoxy, c) branched or unbranched EC 1 -C 5 alkyl, d) branched or unbranched EC 2 -C 5 alkenyl, e) branched or unbranched EC 2 -C 5 alkynyl, f) hydroxyl, g) branched or unbranched C 1 -C 5 alkyl, or h) branched or unbranched C 1 -C 5 alkoxy, with the proviso that exactly one of the substituents R 3 or R 4 contains an E and the other substituent does not contain E, with the proviso that R 3 is not hydrogen,
  • X ' and X " independently of one another are a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, c) substituted or unsubstituted alkylaryl or d) substituted or unsubstituted heteroaryl,
  • G '" for a) branched or unbranched OC 1 -C 5 alkyl, b) branched or unbranched 0-C 2 -C 5 alkenyl, c) branched or unbranched 0-C 1 -C 5 AlKyI- (OC 1 -C 4 BIkYl) n -OC 1 -C 4 alkyl, d) branched or unbranched 0-C 2 -C 5 alkynyl, or e) triphenylmethoxy,
  • R 5 and R 6 represent a) hydrogen b) hydroxyl, c) branched or unbranched C 1 -C 5 alkyl, d) branched or unbranched C 1 -C 5 alkoxy or e) R 7 -E ' , with the proviso that that exactly one of the substituents R 5 or R 6 contains an E ' and the other substituent does not contain E', with the proviso that R 5 is not hydrogen,
  • R 7 is a) branched or unbranched C 2 -C 5 alkoxy, b) branched or unbranched C 1 -C 5 alkyl, c) branched or unbranched C 2 -C 5 alkenyl, or d) branched or unbranched C 2 -C 5 Alkynyl,
  • N-1-methylcyclobutylcarbonyl m) N-vinylcarbonyl, n) N-allylcarbonyl, o) N-adamantylcarbonyl, p) N-diphenylmethylcarbonyl, q) N-cinnamylcarbonyl, r) N-formyl, or s) N-benzoyl , t) N (H) -trityl, u) N (H) -p-methoxyphenyl-diphenylmethyl, v) N (H) -di- (p-methoxyphenyl) -phenylmethyl,
  • X 'and X "independently of one another are a) branched or unbranched C 1 -C 5 -alkyl, b) substituted or unsubstituted aryl, c) substituted or unsubstituted alkylaryl or d) substituted or unsubstituted heteroaryl, and
  • n 0, 1, 2 or 3.
  • imaging kit containing compounds of general formula IM or IV.
  • composition containing compounds of general formula I, II, III or IV and suitable pharmaceutical carrier substances.
  • R 7 protecting group, eg trityl, Boc, etc.
  • R 7 protecting group, eg Trityl, Boc
  • compound 3 in the presence of a base such as tetra-alkyl ammonium and tetra-alkyl phosphonium carbonate and potassium carbonate, etc.
  • a base such as tetra-alkyl ammonium and tetra-alkyl phosphonium carbonate and potassium carbonate, etc.
  • the reaction preferably proceeds at elevated temperatures.
  • crown ethers such as. B. Kryptofix (K2.2.2) can positively influence the reaction, especially in combination with K 2 CO 3 as the catalysing base.
  • Possible solvents are preferably aprotic, but also protic solvents or aprotic solvent additives, such. As water, can be used.
  • acetonitrile, dimethylsulfoxide or dimethylformamide are used as optimal solvents for radiochemical fluorination with [F-18] fluoride anions.
  • Compound 2 does not usually require purification, but can be treated promptly with the methods described for the reaction of 2 to 1. However, a purification of the compound 2 is possible in principle, preferably by means of a preparative HPLC with a nonpolar phase, such as. Eg RP C-18.
  • the purification of the compound 5 according to formula (I) according to the invention is possible by HPLC, with various purification steps in principle upstream and downstream, such as. For example, cleaning with an RP-C18 cartridge or other separation materials.
  • compound 6 can be reacted in the presence of a base such as, for example, tetraalkylammonium and tetraalkylphosphonium carbonate and potassium carbonate etc. with the appropriate [F-18] fluoride solution.
  • a base such as, for example, tetraalkylammonium and tetraalkylphosphonium carbonate and potassium carbonate etc.
  • the reaction preferably proceeds at elevated temperatures.
  • crown ethers such as. B. Kryptofix (K2.2.2) can positively influence the reaction, especially in combination with K 2 CO 3 as the catalysing base.
  • Possible solvents are preferably aprotic, but also protic solvents or aprotic solvent additives, such. As water, can be used.
  • acetonitrile, dimethylsulfoxide or dimethylformamide are used as optimal solvents for radiochemical fluorination with [F-18] fluoride anions.
  • Compound 6 does not usually require purification, but can be treated promptly with the methods described for the reaction of 6 to 6.
  • purification of compound 6 is possible in principle, preferably by means of preparative HPLC with a non-polar phase, such as. Eg RP C-18.
  • a cleaning by means of cartridges is possible.
  • the radiochemical fluorination of tosylate 10 whose synthesis was carried out analogously to the method described in the literature (X. Zhang Tetrahedron Leu., 2001, 42, 5335-5338) from 8, to the [F-18] -labeled glutamic acid derivative 7 is known to those skilled in the art feasible methods (see Scheme 11).
  • compound 10 in the presence of a base such as tetra-alkyl ammonium and tetra-alkyl phosphonium carbonate and potassium carbonate, etc. can be reacted with the appropriate [F-18] fluoride solution.
  • the reaction preferably proceeds at elevated temperatures.
  • crown ethers such as. B. Kryptofix (K2.2.2) can positively influence the reaction, especially in combination with K 2 CO 3 as a catalyzing
  • Possible solvents are preferably aprotic, but also protic solvents or aprotic solvent additives, such.
  • water can be used.
  • Compound 7 does not usually require purification, but can be treated promptly with the methods described for the reaction of 7 to 5. However, a purification of the compound 7 is possible in principle, preferably by means of a preparative HPLC with a nonpolar phase, such as. Eg RP C-18.
  • the starting compound for the radiochemical fluorination to 6 is also the bromide 8a, which can be obtained from 9 in two stages: by alkylation of 9 by 1, 2-dibromoethane to the bromoethoxy-pyrrolidine derivative 8b and subsequent oxidation, for example by means of ruthenium ( III) compounds as described in Examples 3a and 3b.
  • the compounds 18 and 19 in the presence of a base such as tetra-alkyl ammonium and tetra-alkyl phosphonium carbonate and potassium carbonate, etc. can be reacted with the corresponding [F-18] fluoride solution.
  • the reaction preferably proceeds at elevated temperatures.
  • the addition of Kronenethem such.
  • Kryptofix K2.2.2
  • Possible solvents are preferably aprotic, but also protic Solvent or aprotic solvent additives such. As water, can be used.
  • acetonitrile, dimethylsulfoxide or dimethylformamide are used as optimal solvents for radiochemical fluorination with [F-18] fluoride anions.
  • the compounds 16 and 17 usually need not be subjected to purification, but can be treated promptly with the methods described for the reaction of 16 to 14 and 17 to 15, respectively. However, a purification of the compounds 16 or 17 is in principle possible, preferably by means of a preparative HPLC with a nonpolar phase, such as. Eg RP C-18.
  • the synthesis of the F-19 reference compounds 21 and 22 can be carried out by alkylation of the glutamic acid derivative 20 (Scheme 15).
  • the compound 20 can also be alkylated with iodides, preferably with diiodides analogously to Example 2a.
  • Each of the S-forms of the chiral centers in C-3 or / and C-4 position of a compound of the present invention of the formula (I), formula (II), formula (III), formula (IV) or formula ( V) includes.
  • both "ice” and “trans” isomers are part of the present invention.
  • tautomeric forms can, such.
  • Keto-enol tautomerism all tautomeric forms are included in the present invention, which forms may be in equilibrium or, preferably, in a form.
  • the compounds of the general formula I or II and their preferred embodiments are used as medicaments.
  • the compounds of general formula I or II according to the invention and their preferred embodiments are used in the diagnosis of physiological or pathological conditions. These compounds are preferably used in non-invasive PET-based diagnosis on the human or animal body.
  • the compounds of the general formula I or II according to the invention and their preferred embodiments are particularly preferably used in the diagnosis of tumor diseases.
  • tumors are malignancies of the gastrointestinal or colorectal tract, liver, pancreatic, renal, bladder, thyroid, prostate, endometrial, ovarian, testes, melanoma, small cell and non-small cell bronchial carcinoma, dysplastic oral mucosa carcinoma, invasive oral cancer;
  • Breast cancer including hormone-dependent and hormone-independent breast cancer, squamous cell carcinoma, neurological cancers including neuroblastoma, glioma, astrocytoma, osteosarcoma, meningioma; soft tissue sarcoma;
  • Hemangioam and endocrine tumors including pituitary adenomas, chromocytomas, paraganglions, haematological malignancies including lymphoma and leukemias; or metastases of any of the above tumors.
  • the compounds of the general formula I or II according to the invention and their preferred embodiments are used for the preparation of a medicament for the diagnosis of tumor diseases.
  • tumors are malignancies of the gastrointestinal or colorectal tract, liver, pancreas, kidney, bladder, thyroid, prostate, endometrial, ovarian, testes, melanoma, small cell and non-small cell bronchial carcinoma, dysplastic oral mucosa Carcinoma, invasive oral cancer;
  • Breast cancer including hormone-dependent and hormone-independent breast cancer, squamous cell carcinoma, neurological cancers including neuroblastoma, glioma, astrocytoma, osteosarcoma, meningioma, soft tissue sarcoma;
  • Hemangioam and endocrine tumors including pituitary adenomas, chromocytomas, paragangliomas, haematological malignancies including lymphoma and leukemias; or metastases of any of the above tumors.
  • a pharmaceutical preparation which in addition to the active ingredient for enteral or parenteral administration suitable pharmaceutical, organic or inorganic inert carrier materials, such as, for example, water, gelatin, gum arabic , Lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • suitable pharmaceutical, organic or inorganic inert carrier materials such as, for example, water, gelatin, gum arabic , Lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc.
  • the invention relates to a device (kit) comprising at least one compound of the formula I, II, IM, IV or V.
  • aryl as used herein by itself or as part of another group refers to mono- or bicyclic aromatic groups which may include from six to ten carbon atoms in the ring, such as e.g. For example, phenyl or naphthyl, and may be substituted as desired.
  • the aryl groups may be substituted at any convenient point resulting in a stable compound by one or more of the group: hydroxy, halogen, C 1 -C 5 alkyl, C 1 -C 5 alkoxy, cyano, CF 3 , Nitro.
  • substituents are methoxy, ethoxy, propoxy-.iso-propoxy, hydroxy, fluorine, chlorine,
  • halogen is in each case fluorine, chlorine, bromine or iodine to understand.
  • alkyl refers to saturated carbon chains which may be straight-chain or branched, especially methyl, ethyl, n-propyl, iso-propyl , n-butyl, isobutyl, tert-butyl or n-pentyl, 2,2-dimethylpropyl, 2-methylbutyl or 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, n-nonyl or n-decyl groups.
  • C 1 -C 10 -alkyl is optionally interrupted by one or more O, S, or N.
  • alkenyl substituents are in each case straight-chain or branched, where the following are, for example, the following radicals: vinyl, propen-1-yl, propen-2-yl, but-1-en-1-yl, but-1-en-2-yl , But-2-en-1-yl, but-2-en-2-yl, 2-methylprop-2-en-1-yl, 2-methylprop-1-en-1-yl, But -1-en-3-yl, but-3-en-1-yl, AIIyI.
  • Halogen is fluoro, chloro, bromo and iodo. Chloro, bromo and iodo are preferred.
  • the C T Cs-alkoxy groups may be straight chain or branched and stand for a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy or n-pentoxy, 2 2-Dimethylpropoxy, 2-methylbutoxy or 3-methylbutoxy group.
  • the heteroaryl radical comprises in each case 5-10 ring atoms and may contain one or more, identical or different heteroatoms, such as oxygen, nitrogen or sulfur in the ring instead of one carbon atom, and may additionally each be benzo-fused.
  • heteroatoms such as oxygen, nitrogen or sulfur in the ring instead of one carbon atom, and may additionally each be benzo-fused.
  • 5-rings thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, etc.
  • 6-rings pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc.
  • [F-18] Fluoride was prepared via the [O-18] (p, n) [F-18] reaction in a cyclotron.
  • the isotope solution (4 GBq) was placed on a Sep-Pack Light QMA cartridge.
  • the [F-18] fluoride was eluted from the cartridge with a Kryptofix 2.2.2 / potassium carbonate solution (5 mg K2.2.2, 1 mg potassium carbonate, acetonitrile (1, 5 ml), water (0.5 ml)).
  • the solvent was removed at 120 ° C. in a stream of nitrogen with the addition of acetonitrile (three times 1 mL).
  • [F-18] Fluoride was prepared via the [O-18] (p, n) [F-18] reaction in a cyclotron.
  • the isotope solution (5.2 GBq) was placed on a Sep-Pack Light QMA cartridge.
  • the [F-18] fluoride was eluted from the cartridge with a Kryptofix 2.2.2 / potassium carbonate solution (5 mg K2.2.2, 1 mg potassium carbonate, acetonitrile (1.5 mL), water (0.5 mL)).
  • the solvent was removed at 120 ° C. in a stream of nitrogen with the addition of acetonitrile (three times 1 mL).
  • the intermediate was purified by HPLC (C18, acetonitrile / water).
  • the HPLC fraction was diluted with water (ca 50 mL) and passed through a C18 cartridge.
  • the intermediate was eluted with 1 mL acetonitrile.
  • the intermediate was purified by HPLC (C18, acetonitrile / water).
  • HPLC fraction was diluted with water (ca 50 mL) and passed through a C18 cartridge.
  • the intermediate was eluted with 1 mL acetonitrile. In a synthesis time of 70 min were 1, 3
  • L-Glu L-configured glutamic acid
  • 4S- (3-fluoropropyl) -L-Glu showed a much better inhibition than other investigated derivatives. For example, 1 mM 4S- (3-fluoropropyl) -L-Glu reduced> 94% tracer uptake to 5.4%.
  • (2S, 4S) -2-amino-4- (3- [F-18] fluoropropyl) -pentanedioic acid was studied in cell experiments on A549 and H460 tumor cells (both non-small cell bronchial carcinoma human cell lines) , A temporal dependence of the cell uptake was observed. After 30 min of incubation, a uptake of 899,000 cpm per 100,000 cells for (2S, 4S) -2-amino-4- (3- [F-18] fluoropropyl) pentanedioic acid was measured.
  • (2S, 4S) -2-amino-4- (3- [F-18] fluoropropyl) -pentanedioic acid accumulates more strongly in these tumor cells than the "gold standard” [F-18JFDG after 30 min of incubation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des composés et la synthèse d'acide L-glutamique marqué au [F-18] et de L-glutamate marqué au [F-18], leurs dérivés selon la formule (I) et leurs utilisations.
EP09749581A 2008-05-20 2009-05-14 Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production Withdrawn EP2282982A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09749581A EP2282982A1 (fr) 2008-05-20 2009-05-14 Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08075510A EP2123621A1 (fr) 2008-05-20 2008-05-20 Nouveaux acides de glutamine L marqués au {F-18} et dérivés de glutamine L (I), leur utilisation et leur procédé de fabrication
EP09749581A EP2282982A1 (fr) 2008-05-20 2009-05-14 Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production
PCT/EP2009/003420 WO2009141091A1 (fr) 2008-05-20 2009-05-14 Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production

Publications (1)

Publication Number Publication Date
EP2282982A1 true EP2282982A1 (fr) 2011-02-16

Family

ID=39970942

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08075510A Withdrawn EP2123621A1 (fr) 2006-11-01 2008-05-20 Nouveaux acides de glutamine L marqués au {F-18} et dérivés de glutamine L (I), leur utilisation et leur procédé de fabrication
EP09749581A Withdrawn EP2282982A1 (fr) 2008-05-20 2009-05-14 Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08075510A Withdrawn EP2123621A1 (fr) 2006-11-01 2008-05-20 Nouveaux acides de glutamine L marqués au {F-18} et dérivés de glutamine L (I), leur utilisation et leur procédé de fabrication

Country Status (25)

Country Link
US (3) US20110165076A1 (fr)
EP (2) EP2123621A1 (fr)
JP (2) JP2011520932A (fr)
KR (1) KR101636245B1 (fr)
CN (2) CN102083772A (fr)
AR (1) AR073845A1 (fr)
AU (1) AU2009250130B2 (fr)
BR (1) BRPI0913128A2 (fr)
CA (1) CA2723596C (fr)
CL (1) CL2009001240A1 (fr)
CO (1) CO6331330A2 (fr)
CR (1) CR11800A (fr)
DO (1) DOP2010000358A (fr)
EA (1) EA025217B1 (fr)
EC (1) ECSP10010617A (fr)
HK (1) HK1205099A1 (fr)
IL (1) IL208662A0 (fr)
MX (1) MX2010012636A (fr)
NZ (1) NZ589350A (fr)
PA (1) PA8827401A1 (fr)
PE (1) PE20091956A1 (fr)
SV (1) SV2010003739A (fr)
TW (2) TW201439043A (fr)
UY (1) UY31835A (fr)
WO (1) WO2009141091A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123621A1 (fr) 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Nouveaux acides de glutamine L marqués au {F-18} et dérivés de glutamine L (I), leur utilisation et leur procédé de fabrication
BRPI0718055A2 (pt) 2006-11-01 2013-11-05 Bayer Schering Pharma Ag Ácido l-glutâmico marcado com (f-18), l-glutamina maracada com (f-18), seus derivados e seu uso, bem como processos para sua preparação
US20130149243A1 (en) * 2009-11-17 2013-06-13 Bayer Intellectual Property Gmbh Method for production of f-18 labeled glutamic acid derivatives
DE102010036356A1 (de) * 2010-07-12 2012-01-12 Abx Advanced Biochemical Compounds Gmbh Vorrichtung zur Synthese radioaktiv markierter Verbindungen
DE102010063974B4 (de) * 2010-12-22 2021-10-07 Thomas Rühl Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung
EP2520557A1 (fr) * 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Nouveaux précurseurs de dérivés du glutamate
EP2520556A1 (fr) 2011-05-03 2012-11-07 Bayer Pharma Aktiengesellschaft Acides aminés radiomarqués pour imagerie de diagnostic
US8784774B2 (en) * 2011-09-16 2014-07-22 General Electric Company Labeled molecular imaging agents and methods of use
CN103333079B (zh) * 2013-07-03 2016-08-17 广东回旋医药科技股份有限公司 亚氨基酸类pet显像剂及其制备方法与应用
US9468692B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
US9468693B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
CN106631863B (zh) * 2016-09-06 2018-08-17 中山大学附属第一医院 亚谷氨酸类pet显像剂的放射合成方法
CN109369445B (zh) * 2018-11-20 2021-10-15 首都医科大学 用于诊断和治疗的放射性谷氨酰胺衍生物及其制备方法
WO2023229997A1 (fr) * 2022-05-23 2023-11-30 Board Of Regents, The University Of Texas System Production automatisée de [18f]fspg conforme à la cgmp pour examen clinique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620522A1 (de) 1964-12-23 1970-04-23 Takeda Chemical Industries Ltd Verfahren zur Herstellung von 5-substituierten Isoxazolidonverbindungen
FR1461184A (fr) 1964-12-23 1966-01-07 Takeda Chemical Industries Ltd Procédé de préparation d'isoxazolidones substituées en position 5
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US5264570A (en) 1992-08-05 1993-11-23 General Electric Company Method for making 2-[18 F]fluoro-2-deoxy-D-glucose
GB9324872D0 (en) 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
WO2002014261A2 (fr) 2000-08-10 2002-02-21 Eli Lilly And Company Composes chimiques
AU2001288658A1 (en) 2000-09-01 2002-03-13 Annovis, Inc. Screen for glutamate reuptake inhibitors, stimulators, and modulators
DE10223451A1 (de) 2002-05-25 2003-12-24 Abx Gmbh Verfahren zur Herstellung von 18F-fluorierten alpha-Aminosäuren
PL375183A1 (en) 2002-08-02 2005-11-28 Mallinckrodt Inc. Radioactively labelled amino acid analogues, their preparation and use
US7483732B2 (en) 2004-04-15 2009-01-27 Boston Scientific Scimed, Inc. Magnetic resonance imaging of a medical device and proximate body tissue
BRPI0718055A2 (pt) * 2006-11-01 2013-11-05 Bayer Schering Pharma Ag Ácido l-glutâmico marcado com (f-18), l-glutamina maracada com (f-18), seus derivados e seu uso, bem como processos para sua preparação
EP2123621A1 (fr) 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Nouveaux acides de glutamine L marqués au {F-18} et dérivés de glutamine L (I), leur utilisation et leur procédé de fabrication
EP1923382A1 (fr) * 2006-11-18 2008-05-21 Bayer Schering Pharma Aktiengesellschaft L-acide glutamique marqué au fluor 18, glutamine marquée au fluor 18, leurs derivés ainsi que procédés de leur préparation
EP2123620A1 (fr) 2008-05-20 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Dérivés de l'acide L-glutamique marqué en {F-19} et de L-glutamine (III), leur utilisation et procédé pour les obtenir

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009141091A1 *

Also Published As

Publication number Publication date
CO6331330A2 (es) 2011-10-20
ECSP10010617A (es) 2010-12-30
BRPI0913128A2 (pt) 2016-01-05
CA2723596C (fr) 2016-08-02
US20140154183A1 (en) 2014-06-05
CN104356019A (zh) 2015-02-18
EA025217B1 (ru) 2016-12-30
US20100290991A1 (en) 2010-11-18
KR101636245B1 (ko) 2016-07-07
US9308282B2 (en) 2016-04-12
KR20110009165A (ko) 2011-01-27
SV2010003739A (es) 2011-04-06
IL208662A0 (en) 2010-12-30
EA201001766A1 (ru) 2011-12-30
CN102083772A (zh) 2011-06-01
US20110165076A1 (en) 2011-07-07
PA8827401A1 (es) 2009-12-16
AU2009250130A1 (en) 2009-11-26
PE20091956A1 (es) 2010-02-05
DOP2010000358A (es) 2010-12-31
EP2123621A1 (fr) 2009-11-25
UY31835A (es) 2010-01-05
WO2009141091A1 (fr) 2009-11-26
CR11800A (es) 2011-01-12
WO2009141091A8 (fr) 2010-11-11
AU2009250130B2 (en) 2014-08-21
TW201439043A (zh) 2014-10-16
NZ589350A (en) 2012-08-31
TW201008585A (en) 2010-03-01
JP2011520932A (ja) 2011-07-21
AR073845A1 (es) 2010-12-09
JP2015042671A (ja) 2015-03-05
CL2009001240A1 (es) 2010-07-19
MX2010012636A (es) 2010-12-06
HK1205099A1 (en) 2015-12-11
CA2723596A1 (fr) 2009-11-26

Similar Documents

Publication Publication Date Title
EP2282982A1 (fr) Nouveaux dérivés (i) d'acide l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production
EP2086924B1 (fr) Acide l-glutamique marque au [f-18], l-glutamine marquée au [f-18], leurs derives et leur utilisation, ainsi que leur procede de fabrication
EP0417870B1 (fr) Chélates pour complexation d'isotopes radioactifs, leurs complexes et leur utilisation en diagnostic et thérapie
DE60312136T2 (de) Radiofluorierungsverfahren
WO2009141079A1 (fr) Nouveaux dérivés (ii) d'acides l-glutamique et de l-glutamine marqués au [f-18], leur utilisation et leur procédé de production
US9017645B2 (en) Homoglutamic acid derivatives
EP1923382A1 (fr) L-acide glutamique marqué au fluor 18, glutamine marquée au fluor 18, leurs derivés ainsi que procédés de leur préparation
EP3216796B1 (fr) Composé de phosphonium et son procédé de production
EP0692981B1 (fr) Agents chelateurs de type xn 1?s 1?x' d'isotopes radioactifs, leur complexes metalliques et leurs utilisations diagnostiques et therapeutiques
EP0692980B1 (fr) Agents chelateurs de type s3n2 d'isotopes radioactifs, leurs complexes metalliques et leurs utilisations en diagnostique et therapeutique
CN109369445B (zh) 用于诊断和治疗的放射性谷氨酰胺衍生物及其制备方法
DE19632052C2 (de) Benzamidderivate und deren Verwendung zur Diagnose und Behandlung von Tumoren, insbesondere Melanomen
DE60210432T2 (de) Verfahren zur synthese heteroatomhaltiger liganden und dafür verwendetes neues zwischenprodukt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PIRAMAL IMAGING SA

17Q First examination report despatched

Effective date: 20121212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130625